Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 315

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 315
---
 general conditions of the securities markets at the time of the offering
and such other factors as were deemed relevant.

<div align='center'>185</div>

Electronic Distribution

A prospectus in electronic
format may be made available on a website maintained by the placement agent. In connection with the offering, the placement agent or
selected dealers may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that are printable
as Adobe® PDF will be used in connection with this offering.

Other than the prospectus
in electronic format, the information on the placement agent’s website and any information contained in any other website maintained
by the placement agent is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been
approved and/or endorsed by us or the placement agent in its capacity as placement agent and should not be relied upon by investors.

Certain Relationships

The placement agent and
its affiliates have provided and may in the future provide, from time to time, investment banking and financial advisory services to
us in the ordinary course of business, for which they may receive customary fees and commissions.

Trading Market

Our Common Stock is listed
on the Nasdaq Global Market under the symbol “CERO.” There is no established public trading market for the Pre-Funded
Warrants or the Offered Common Warrants to be sold in this offering, and we do not expect a market for the Pre-Funded Warrants or
the Offered Common Warrants to develop. In addition, we do not intend to apply for listing of the Pre-Funded Warrants or Offered Common
Warrants on any national securities exchange.

<div align='center'>186

LEGAL MATTERS</div>

Goodwin Procter LLP has
passed upon the validity of the shares of our Common Stock, Pre-Funded Warrants and Offered Common Warrants offered by this prospectus
and certain other legal matters related to this prospectus. Certain legal matters will be passed upon for the placement agent by Ellenoff
Grossman & Schole LLP.

<div align='center'>EXPERTS</div>

The financial statements
of Phoenix Biotech Acquisition Corp. as of December 31, 2023 and 2022, and each of the years in the two-year period ended December 31,
2023, included in this prospectus have been audited by Citrin Cooperman & Company, LLP, an independent registered public accounting
firm, as stated in their report, which contains an explanatory